endpts.com·Jul 14, 2026
Celcuity has received FDA approval for its breast cancer drug Revtorpyk, which aims to enhance treatment options compared to existing therapies from Novartis and Roche.
Celcuity, a small public biotech company, achieved FDA approval for its breast cancer drug Revtorpyk, designed to improve upon treatments from major players like Novartis and Roche. This development highlights the potential for smaller biotech firms to compete in the oncology space by targeting niche advancements, which could be a signal for potential investment or partnership opportunities in innovative drug development.